Neuropeptide Y Y1 receptor antagonism increases bone mass in mice

Bone

Volumn 51, Issue 1, 2012, Pages 8-16

  Sousa, Daniela M ^a,b   Baldock, Paul A ^c,d   Enriquez, Ronaldo F ^c   Zhang, Lei ^c   Sainsbury, Amanda ^c,d   Lamghari, Meriem ^a,b   Herzog, Herbert ^c,d  

^a INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Neuropeptide yY; Oral drug administration; Osteopenia; Y1 receptor antagonism

Indexed keywords

CORTICOSTERONE; GLUCOSE; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NEUROPEPTIDE Y;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MASS; BONE METABOLISM; BONE STRENGTH; CANCELLOUS BONE; CONTROLLED STUDY; CORTICAL BONE; CORTICOSTERONE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENERGY METABOLISM; FEMUR; FOOD INTAKE; GLUCOSE HOMEOSTASIS; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; SIGNAL TRANSDUCTION; TRABECULAR BONE;

ANIMALS; ARGININE; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HOMEOSTASIS; MALE; MICE; MICE, INBRED C57BL; OSTEOGENESIS; RECEPTORS, NEUROPEPTIDE Y;

EID: 84859915620     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.03.020     Document Type: Article

References (37)

1. Karaguzel G., Holick M.F. Diagnosis and treatment of osteopenia. Rev Endocr Metab Disord 2010, 11:237-251.
2. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22:465-475.
3. Nguyen N.D., Ahlborg H.G., Center J.R., Eisman J.A., Nguyen T.V. Residual lifetime risk of fractures in women and men. J Bone Miner Res 2007, 22:781-788.
4. Goltzman D. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov 2002, 1:784-796.
5. Jorgensen N.R., Schwarz P. Effects of anti-osteoporosis medications on fracture healing. Curr Osteoporos Rep 2011, 9:149-155.
6. Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys 2008, 473:231-236.
7. Teixeira L., Sousa D.M., Nunes A.F., Sousa M.M., Herzog H., Lamghari M. NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors. J Cell Biochem 2009, 107:908-916.
8. Lee N.J., Doyle K.L., Sainsbury A., Enriquez R.F., Hort Y.J., Riepler S.J., et al. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J Bone Miner Res 2010, 25:1736-1747.
9. Blomqvist A.G., Herzog H. Y-receptor subtypes-how many more?. Trends Neurosci 1997, 20:294-298.
10. Zhang L., Macia L., Turner N., Enriquez R.F., Riepler S.J., Nguyen A.D., et al. Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion. Int J Obes (Lond) 2010, 34:357-373.
11. Painsipp E., Sperk G., Herzog H., Holzer P. Delayed stress-induced differences in locomotor and depression-related behaviour in female neuropeptide-Y Y1 receptor knockout mice. J Psychopharmacol 2010, 24:1541-1549.
12. Movafagh S., Hobson J.P., Spiegel S., Kleinman H.K., Zukowska Z. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J 2006, 20:1924-1926.
13. Hansel D.E., Eipper B.A., Ronnett G.V. Neuropeptide Y functions as a neuroproliferative factor. Nature 2001, 410:940-944.
14. Baldock P.A., Allison S.J., Lundberg P., Lee N.J., Slack K., Lin E.-J.D., et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 2007, 282:19092-19102.
15. Lee N.J., Nguyen A.D., Enriquez R.F., Doyle K.L., Sainsbury A., Baldock P.A., et al. Osteoblast specific Y1 receptor deletion enhances bone mass. Bone 2011, 48:461-467.
16. Lundberg P., Allison S.J., Lee N.J., Baldock P.A., Brouard N., Rost S., et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem 2007, 282:19082-19091.
17. Igwe J.C., Jiang X., Paic F., Ma L., Adams D.J., Baldock P.A., et al. Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J Cell Biochem 2009, 108:621-630.
18. Zhang L., Bijker M.S., Herzog H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther 2011, 131:91-113.
19. Yulyaningsih E., Zhang L., Herzog H., Sainsbury A. NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol 2011, 163:1170-1202.
20. Wieland H.A., Engel W., Eberlein W., Rudolf K., Doods H.N. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol 1998, 125:549-555.
21. Polidori C., Ciccocioppo R., Regoli D., Massi M. Neuropeptide Y receptor(s) mediating feeding in the rat: characterization with antagonists. Peptides 2000, 21:29-35.
22. Dailey M.J., Bartness T.J. Appetitive and consummatory ingestive behaviors stimulated by PVH and perifornical area NPY injections. Am J Physiol Regul Integr Comp Physiol 2009, 296:R877-R892.
23. Zhang L., Lee N.J., Nguyen A.D., Enriquez R.F., Riepler S.J., Stehrer B., et al. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes Obes Metab 2010, 12:591-603.
24. Matsuda H., Brumovsky P.R., Kopp J., Pedrazzini T., Hokfelt T. Distribution of neuropeptide Y Y1 receptors in rodent peripheral tissues. J Comp Neurol 2002, 449:390-404.
25. Baldock P.A., Sainsbury A., Allison S., Lin E.-J.D., Couzens M., Boey D., et al. Hypothalamic control of bone formation: distinct actions of leptin and Y2 receptor pathways. J Bone Miner Res 2005, 20:1851-1857.
26. Kushi A., Sasai H., Koizumi H., Takeda N., Yokoyama M., Nakamura M. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci U S A 1998, 95:15659-15664.
27. Kempna P., Korner M., Waser B., Hofer G., Nuoffer J.M., Reubi J.C., et al. Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors. Mol Cell Endocrinol 2010, 314:101-109.
28. Burcelin R., Brunner H., Seydoux J., Thorensa B., Pedrazzini T. Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice. Peptides 2001, 22:421-427.
29. Buckwalter J.A., Cooper R.R. Bone structure and function. Instr Course Lect 1987, 36:27-48.
30. El-Sherif N., Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J 2011, 18:233-245.
31. Amano S., Arai M., Goto S., Togari A. Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells. Biochim Biophys Acta 2007, 1770:966-973.
32. Wheway J., Mackay C.R., Newton R.A., Sainsbury A., Boey D., Herzog H., et al. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med 2005, 202:1527-1538.
33. Datta H.K., Ng W.F., Walker J.A., Tuck S.P., Varanasi S.S. The cell biology of bone metabolism. J Clin Pathol 2008, 61:577-587.
34. Bedoui S., Kawamura N., Straub R.H., Pabst R., Yamamura T., von Hörsten S. Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol 2003, 134:1-11.
35. Allison S.J., Baldock P.A., Enriquez R.F., Lin E., During M., Gardiner E.M., et al. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J Bone Miner Res 2009, 24:294-304.
36. Frolik C.A., Black E.C., Cain R.L., Satterwhite J.H., Brown-Augsburger P.L., Sato M., et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 2003, 33:372-379.
37. Vahle J.L., Long G.G., Sandusky G., Westmore M., Ma Y.L., Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426-438.